$ELVN
Enliven Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023041349 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.640M $4.950M $3.080M
YoY Change -0.19% 20.38% -11.44%
% of Gross Profit
Research & Development $19.61M $15.18M $180.0K
YoY Change 10672.53% 104.93% -98.34%
% of Gross Profit
Depreciation & Amortization $79.00K $74.00K $0.00
YoY Change -24.04% -84.68% -100.0%
% of Gross Profit
Operating Expenses $24.25M $20.13M $3.260M
YoY Change 401.93% 74.76% -77.26%
Operating Profit -$24.25M -$20.13M
YoY Change 401.93% 74.76%
Interest Expense $3.492M $3.413M $510.0K
YoY Change 1342.98% 3002.73% 608.33%
% of Operating Profit
Other Income/Expense, Net $3.479M $3.413M $20.00K
YoY Change 1467.12% 4640.28% -135.09%
Pretax Income -$20.77M -$16.72M $32.27M
YoY Change 350.64% 46.04% -325.36%
Income Tax $0.00 $90.00K
% Of Pretax Income 0.28%
Net Earnings -$20.77M -$16.72M $32.19M
YoY Change 350.62% 46.05% -324.81%
Net Earnings / Revenue
Basic Earnings Per Share -$0.51 -$0.41
Diluted Earnings Per Share -$0.51 -$0.41 $4.83
COMMON SHARES
Basic Shares Outstanding 41.15M 41.11M 26.29M
Diluted Shares Outstanding 41.03M 40.96M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $263.5M $277.9M $88.20M
YoY Change 368.0% 360.56% -2.3%
Cash & Equivalents $73.85M $125.7M $88.20M
Short-Term Investments $189.6M $152.2M $0.00
Other Short-Term Assets $5.100M $5.300M $2.200M
YoY Change 82.14% 35.34% -9.02%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $268.6M $283.2M $89.64M
YoY Change 354.46% 340.7% -3.3%
LONG-TERM ASSETS
Property, Plant & Equipment $806.0K $867.0K $890.0K
YoY Change 725.71% 256.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.614M $3.406M $2.323M
YoY Change 1846.29% 1227.43%
Total Long-Term Assets $5.435M $5.326M $2.323M
YoY Change 1199.02% 144.53%
TOTAL ASSETS
Total Short-Term Assets $268.6M $283.2M $89.64M
Total Long-Term Assets $5.435M $5.326M $2.323M
Total Assets $274.0M $288.5M $91.96M
YoY Change 363.66% 346.14% -1.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.493M $2.843M $149.0K
YoY Change 94.65% 150.48% -93.69%
Accrued Expenses $10.60M $6.600M $1.681M
YoY Change 908.56% 283.28% -63.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.08M $9.147M $1.830M
YoY Change 564.41% 177.01% -74.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $214.0K $360.0K $659.0K
YoY Change 62.32%
Total Long-Term Liabilities $214.0K $360.0K $659.0K
YoY Change 62.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.08M $9.147M $1.830M
Total Long-Term Liabilities $214.0K $360.0K $659.0K
Total Liabilities $12.29M $9.507M $1.830M
YoY Change 576.18% 187.92% -75.97%
SHAREHOLDERS EQUITY
Retained Earnings -$135.1M -$114.3M -$146.0M
YoY Change -24.19% -34.16% -1.01%
Common Stock $41.00K $41.00K $27.00K
YoY Change 51.85% 51.85% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $261.7M $279.0M $90.13M
YoY Change
Total Liabilities & Shareholders Equity $274.0M $288.5M $91.96M
YoY Change 363.66% 346.14% -1.8%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q4
OPERATING ACTIVITIES
Net Income -$20.77M -$16.72M $32.19M
YoY Change 350.62% 46.05% -324.81%
Depreciation, Depletion And Amortization $79.00K $74.00K $0.00
YoY Change -24.04% -84.68% -100.0%
Cash From Operating Activities -$15.90M -$12.05M -$1.880M
YoY Change 278.48% -2.25% -84.94%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $90.00K $0.00
YoY Change -195.24% -143.48%
Acquisitions
YoY Change
Other Investing Activities -$35.53M -$151.4M $41.82M
YoY Change -253.78% -2435.8% -388.59%
Cash From Investing Activities -$35.55M -$151.5M $41.82M
YoY Change -254.0% -2514.28% -388.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -420.0K -2.820M -1.230M
YoY Change 12200.0%
NET CHANGE
Cash From Operating Activities -15.90M -12.05M -1.880M
Cash From Investing Activities -35.55M -151.5M 41.82M
Cash From Financing Activities -420.0K -2.820M -1.230M
Net Change In Cash -51.87M -166.4M 38.71M
YoY Change -374.69% 2649.79% -243.44%
FREE CASH FLOW
Cash From Operating Activities -$15.90M -$12.05M -$1.880M
Capital Expenditures $20.00K $90.00K $0.00
Free Cash Flow -$15.92M -$12.14M -$1.880M
YoY Change 280.86% 0.17% -84.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001672619
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201912Member
elvn Lease Commencement Date
LeaseCommencementDate
2022-07-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39247
dei Entity Registrant Name
EntityRegistrantName
ENLIVEN THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1523849
dei Entity Address Address Line1
EntityAddressAddressLine1
6200 Lookout Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Boulder
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80301
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
647-8519
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ELVN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41151111
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
125715000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75536000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
152150000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5310000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2217000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
283175000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
77753000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
867000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
890000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
475000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
626000
CY2023Q2 elvn Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
524000
CY2022Q4 elvn Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
3975000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
54000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
54000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3406000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2023Q2 us-gaap Assets
Assets
288501000
CY2022Q4 us-gaap Assets
Assets
83298000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2843000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3438000
CY2023Q2 elvn Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6304000
CY2022Q4 elvn Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6277000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9147000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9715000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
360000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
659000
CY2023Q2 us-gaap Liabilities
Liabilities
9507000
CY2022Q4 us-gaap Liabilities
Liabilities
10374000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
26264364
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41151111
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41151111
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3570019
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3570019
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
41000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
393373000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6038000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-111000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114309000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82864000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
278994000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-76825000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
288501000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83298000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15183000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7937000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27063000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14996000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4951000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1079000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9489000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2698000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
20134000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9016000
us-gaap Operating Expenses
OperatingExpenses
36552000
us-gaap Operating Expenses
OperatingExpenses
17694000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20134000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9016000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36552000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17694000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3413000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
127000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5107000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
136000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3413000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
127000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5107000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
136000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16721000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8889000
us-gaap Net Income Loss
NetIncomeLoss
-31445000
us-gaap Net Income Loss
NetIncomeLoss
-17558000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-111000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-111000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16832000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8889000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31556000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17558000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.86
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.87
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40961024
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40961024
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3103974
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3103974
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29862182
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29862182
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2991004
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2991004
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-42887000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
228000
CY2022Q1 elvn Vesting Of Restricted Stock And Stock Options
VestingOfRestrictedStockAndStockOptions
64000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
654000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8669000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-50610000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2022Q2 elvn Vesting Of Restricted Stock And Stock Options
VestingOfRestrictedStockAndStockOptions
80000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
701000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8889000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-58713000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-76825000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
140000
CY2023Q1 elvn Vesting Of Restricted Stock And Stock Options
VestingOfRestrictedStockAndStockOptions
73000
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
149749000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4955000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
159544000
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
80241000
CY2023Q1 elvn Reverse Recapitalization Transaction Costs
ReverseRecapitalizationTransactionCosts
9044000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2262000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-14724000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
291416000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
141000
CY2023Q2 elvn Vesting Of Restricted Stock And Stock Options
VestingOfRestrictedStockAndStockOptions
74000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4195000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16721000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-111000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
278994000
us-gaap Net Income Loss
NetIncomeLoss
-31445000
us-gaap Net Income Loss
NetIncomeLoss
-17558000
us-gaap Depreciation
Depreciation
141000
us-gaap Depreciation
Depreciation
91000
us-gaap Share Based Compensation
ShareBasedCompensation
6457000
us-gaap Share Based Compensation
ShareBasedCompensation
1355000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
831000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
5762000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
972000
elvn Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
2000
elvn Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
304000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-965000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1755000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
563000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32893000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17485000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
151430000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
119000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
497000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-151549000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-497000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
281000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
578000
elvn Deferred Offering Costs Related To Initial Public Offering
DeferredOfferingCostsRelatedToInitialPublicOffering
0
elvn Deferred Offering Costs Related To Initial Public Offering
DeferredOfferingCostsRelatedToInitialPublicOffering
164000
elvn Payment Of Deferred Offering Costs Related To The Sales Agreement
PaymentOfDeferredOfferingCostsRelatedToTheSalesAgreement
110000
elvn Payment Of Deferred Offering Costs Related To The Sales Agreement
PaymentOfDeferredOfferingCostsRelatedToTheSalesAgreement
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161365000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
elvn Proceeds From Cash Acquired In Connection With Reverse Recapitalization
ProceedsFromCashAcquiredInConnectionWithReverseRecapitalization
81821000
elvn Proceeds From Cash Acquired In Connection With Reverse Recapitalization
ProceedsFromCashAcquiredInConnectionWithReverseRecapitalization
0
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
8736000
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
234621000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
414000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
50179000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-17568000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75590000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110078000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125769000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92510000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
125715000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92456000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
54000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
54000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125769000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92510000
elvn Deferred Offering Costs Related To The Initial Public Offering Included In Accrued Expenses And Other Current Liabilities
DeferredOfferingCostsRelatedToTheInitialPublicOfferingIncludedInAccruedExpensesAndOtherCurrentLiabilities
0
elvn Deferred Offering Costs Related To The Initial Public Offering Included In Accrued Expenses And Other Current Liabilities
DeferredOfferingCostsRelatedToTheInitialPublicOfferingIncludedInAccruedExpensesAndOtherCurrentLiabilities
97000
elvn Deferred Offering Costs Related To The Sales Agreement Included In Accounts Payable And Accrued Expenses And Other Current Liabilities
DeferredOfferingCostsRelatedToTheSalesAgreementIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
414000
elvn Deferred Offering Costs Related To The Sales Agreement Included In Accounts Payable And Accrued Expenses And Other Current Liabilities
DeferredOfferingCostsRelatedToTheSalesAgreementIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
0
elvn Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
0
elvn Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
3000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
149749000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-06-12
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-4
CY2023Q1 elvn Business Acquisition Exchange Ratio
BusinessAcquisitionExchangeRatio
0.002951
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41011501
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41011501
CY2023Q1 elvn Business Acquisition Exchange Ratio
BusinessAcquisitionExchangeRatio
0.002951
CY2023Q1 elvn Majority Number Of Initial Members Of Board Of Directors
MajorityNumberOfInitialMembersOfBoardOfDirectors
8
CY2023Q1 elvn Business Acquisition Exchange Ratio
BusinessAcquisitionExchangeRatio
0.002951
CY2023Q1 elvn Contigent Value Rights For Each Outstanding Shares
ContigentValueRightsForEachOutstandingShares
one
elvn Payments Received Under Contingent Value Rights Agreement
PaymentsReceivedUnderContingentValueRightsAgreement
0
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
164500000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114300000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
277900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.574%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the determination of fair value of the Company’s common stock, stock-based compensation and accrued research and development expenses. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. Actual results may differ from those estimates or assumptions.</span></p>
elvn Restricted Cash Collateral Of Sublease
RestrictedCashCollateralOfSublease
54000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
54000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
54000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentrations of credit risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.574%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities, as well as restricted cash. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has established guidelines regarding approved investments, credit quality, diversification, liquidity and maturities of investments, which are designed to maintain safety and liquidity. Although management currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any losses in its accounts and believes it is not exposed to significant credit risk on its cash balances.</span></p>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q2 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2023Q2 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2022-01-01
CY2023Q2 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
81821000
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
1044000
CY2023Q1 elvn Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities
2624000
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
80241000
CY2023Q1 elvn Reverse Recapitalization Transaction Costs
ReverseRecapitalizationTransactionCosts
9000000.0
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5000000.0
CY2023Q2 elvn Deferred Offering Costs Related To Merger And Financing Transaction
DeferredOfferingCostsRelatedToMergerAndFinancingTransaction
0
CY2022Q4 elvn Deferred Offering Costs Related To Merger And Financing Transaction
DeferredOfferingCostsRelatedToMergerAndFinancingTransaction
4000000.0
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
152261000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
114000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
152150000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2020Q2 elvn Area Of Leased Office And Laboratory Space
AreaOfLeasedOfficeAndLaboratorySpace
6782
CY2020Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-12-30
CY2021Q1 elvn Area Of Leased Office Space
AreaOfLeasedOfficeSpace
2495
CY2021Q1 elvn Area Of Leased Office Space
AreaOfLeasedOfficeSpace
9277
CY2021Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
12000
CY2022Q2 elvn Lessee Operating Lease Extended Date
LesseeOperatingLeaseExtendedDate
2024-12-30
CY2023Q2 elvn Area Of Leased Office Space
AreaOfLeasedOfficeSpace
18170
CY2023Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
4
CY2023Q2 elvn Operating Lease Remaining Right Of Use Asset
OperatingLeaseRemainingRightOfUseAsset
500000
CY2023Q2 elvn Operating Remaining Lease Liability
OperatingRemainingLeaseLiability
500000
CY2022Q4 elvn Operating Lease Remaining Right Of Use Asset
OperatingLeaseRemainingRightOfUseAsset
600000
CY2022Q4 elvn Operating Remaining Lease Liability
OperatingRemainingLeaseLiability
600000
CY2023Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
82000
CY2022Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
41000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
163000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
82000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
164000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
341000
CY2023Q2 elvn Lessee Operating Lease Liability Payments Due After Year One
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne
0
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
505000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
491000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
329000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
162000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2022Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2023Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1382000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1264000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
515000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
374000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
867000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
890000
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
74000
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
141000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
91000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1778000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2130000
CY2023Q2 elvn Accrued Research And Development Cost Current
AccruedResearchAndDevelopmentCostCurrent
3244000
CY2022Q4 elvn Accrued Research And Development Cost Current
AccruedResearchAndDevelopmentCostCurrent
1918000
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
22439783
CY2023Q2 elvn Accrued Deferred Offering Cost Current
AccruedDeferredOfferingCostCurrent
349000
CY2022Q4 elvn Accrued Deferred Offering Cost Current
AccruedDeferredOfferingCostCurrent
1190000
CY2023Q2 elvn Lease Liability Current
LeaseLiabilityCurrent
329000
CY2022Q4 elvn Lease Liability Current
LeaseLiabilityCurrent
323000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
261000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
269000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
343000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
447000
CY2023Q2 elvn Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6304000
CY2022Q4 elvn Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6277000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41151111
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41151111
CY2023Q2 elvn Common Stock Number Of Shares Subject To Repurchase
CommonStockNumberOfSharesSubjectToRepurchase
146304
CY2022Q4 elvn Common Stock Number Of Shares Subject To Repurchase
CommonStockNumberOfSharesSubjectToRepurchase
252662
CY2023Q2 elvn Common Stock Liability Related To Shares Subject To Repurchase
CommonStockLiabilityRelatedToSharesSubjectToRepurchase
500000
CY2022Q4 elvn Common Stock Liability Related To Shares Subject To Repurchase
CommonStockLiabilityRelatedToSharesSubjectToRepurchase
600000
CY2023Q2 elvn Number Of Vote By Common Stock Holders
NumberOfVoteByCommonStockHolders
1
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
34426351
CY2023Q1 elvn Business Acquisition Exchange Ratio
BusinessAcquisitionExchangeRatio
0.002951
CY2023Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
18216847
CY2023Q1 elvn Pre Merger Financing Amount
PreMergerFinancingAmount
164500000
CY2023Q1 elvn Pre Merger Financing Shares Issued
PreMergerFinancingSharesIssued
12638636
CY2023Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
0
CY2022Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
18216847
elvn Stock Issued During Period Shares Upon Exercise Of Stock Options Outstanding
StockIssuedDuringPeriodSharesUponExerciseOfStockOptionsOutstanding
5722333
CY2022 elvn Stock Issued During Period Shares Upon Exercise Of Stock Options Outstanding
StockIssuedDuringPeriodSharesUponExerciseOfStockOptionsOutstanding
3316671
CY2023Q2 elvn Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
23000
CY2022Q4 elvn Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1906755
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
906265
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8054845
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3316671
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.20
elvn Share Based Compensation Arrangement By Share Based Payment Award Assumption Of Options In Connection With Merger
ShareBasedCompensationArrangementByShareBasedPaymentAwardAssumptionOfOptionsInConnectionWithMerger
449900
elvn Share Based Compensation Arrangements By Share Based Payment Award Assumption Of Options In Connection With Merger Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardAssumptionOfOptionsInConnectionWithMergerWeightedAverageExercisePrice
28.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2165478
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
22.93
elvn Share Based Compensation Arrangement By Share Based Payment Award Options Exercised And Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriod
-141563
elvn Share Based Compensation Arrangements By Share Based Payment Award Options Exercised And Vested In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriodWeightedAverageExercisePrice
3.01
elvn Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelledInPeriod
-68153
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
42.97
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5722333
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.60
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
38500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4195000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
701000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6457000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1355000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16721000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8889000
us-gaap Net Income Loss
NetIncomeLoss
-31445000
us-gaap Net Income Loss
NetIncomeLoss
-17558000
CY2023Q2 elvn Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
41131134
CY2022Q2 elvn Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
3558075
elvn Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
30058872
elvn Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
3538851
CY2023Q2 elvn Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
128384
CY2022Q2 elvn Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
210728
elvn Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
138716
elvn Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
210171
CY2023Q2 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
41726
CY2022Q2 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
243373
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
57974
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
337676
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40961024
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40961024
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3103974
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3103974
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29862182
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29862182
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2991004
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2991004
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.86
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.87
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5772062
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21642916

Files In Submission

Name View Source Status
0000950170-23-041349-index-headers.html Edgar Link pending
0000950170-23-041349-index.html Edgar Link pending
0000950170-23-041349.txt Edgar Link pending
0000950170-23-041349-xbrl.zip Edgar Link pending
elvn-20230630.htm Edgar Link pending
elvn-20230630.xsd Edgar Link pending
elvn-ex31_1.htm Edgar Link pending
elvn-ex31_2.htm Edgar Link pending
elvn-ex32_1.htm Edgar Link pending
elvn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img251746512_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
elvn-20230630_cal.xml Edgar Link unprocessable
elvn-20230630_def.xml Edgar Link unprocessable
elvn-20230630_lab.xml Edgar Link unprocessable
elvn-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
elvn-20230630_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending